GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 3,639 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,639 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $121,287.87. Following the sale, the chief executive officer now owns 95,457 shares of the company’s stock, valued at $3,181,581.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, July 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $33.54, for a total value of $72,245.16.
• On Monday, June 17th, Katherine Stueland sold 7,683 shares of GeneDx stock. The shares were sold at an average price of $28.31, for a total value of $217,505.73.

GeneDx Stock Performance

GeneDx stock traded up $1.59 on Wednesday, hitting $35.26. The company’s stock had a trading volume of 344,758 shares, compared to its average volume of 396,852. The company has a fifty day moving average price of $32.49 and a 200-day moving average price of $22.21. The firm has a market cap of $921.06 million, a P/E ratio of -6.81 and a beta of 2.29. GeneDx Holdings Corp. has a one year low of $1.16 and a one year high of $37.45. The company has a quick ratio of 2.22, a current ratio of 2.38 and a debt-to-equity ratio of 0.27.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.15. GeneDx had a negative net margin of 48.21% and a negative return on equity of 22.71%. On average, equities analysts anticipate that GeneDx Holdings Corp. will post -0.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on WGS. The Goldman Sachs Group lifted their price target on GeneDx from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Craig Hallum upped their target price on shares of GeneDx from $43.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Wells Fargo & Company started coverage on shares of GeneDx in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 price target for the company. Jefferies Financial Group began coverage on shares of GeneDx in a report on Monday, June 3rd. They set a “hold” rating and a $21.00 price objective on the stock. Finally, BTIG Research increased their target price on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Hedge Funds Weigh In On GeneDx

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. increased its position in shares of GeneDx by 227.4% during the 2nd quarter. Point72 Asset Management L.P. now owns 156,745 shares of the company’s stock worth $4,097,000 after purchasing an additional 108,864 shares in the last quarter. Algert Global LLC bought a new stake in GeneDx during the second quarter worth about $356,000. Driehaus Capital Management LLC acquired a new stake in shares of GeneDx during the second quarter worth approximately $11,335,000. The Manufacturers Life Insurance Company bought a new position in shares of GeneDx in the second quarter valued at approximately $290,000. Finally, Millennium Management LLC boosted its holdings in shares of GeneDx by 193.5% in the 2nd quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock worth $8,140,000 after acquiring an additional 205,318 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.